Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19

[1]  T. Efferth,et al.  Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning , 2020, Computers in Biology and Medicine.

[2]  Krystal L. Matthews,et al.  Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo , 2020, Journal of Virology.

[3]  B. Lovetrue.  The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients , 2020, Medical Hypotheses.

[4]  C. Liang,et al.  Peripheral Blood Examination Findings in SARS-CoV-2 Infection , 2020, American journal of clinical pathology.

[5]  P. McCullough,et al.  Considerations for Management of Acute Coronary Syndromes During the SARS-CoV-2 (COVID-19) Pandemic , 2020, The American Journal of Cardiology.

[6]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[7]  S. Cherry,et al.  Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2 , 2020, bioRxiv.

[8]  L. Garmire,et al.  Prediction of repurposed drugs for treating lung injury in COVID-19 , 2020, F1000Research.

[9]  J. Seibel,et al.  The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 , 2020, bioRxiv.

[10]  N. Campillo,et al.  COVID-19: Drug Targets and Potential Treatments , 2020, Journal of medicinal chemistry.

[11]  F. Parazzini,et al.  Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review , 2020, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[12]  H. Biesalski.  Vitamin D deficiency and co-morbidities in COVID-19 patients – A fatal relationship? , 2020, NFS Journal.

[13]  L. Argaud,et al.  Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure? , 2020, Critical Care.

[14]  Philip R. O. Payne,et al.  Repurposing drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2 , 2020, 2006.01226.

[15]  A. Komnos,et al.  Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report , 2020, International Journal of Infectious Diseases.

[16]  O. Toptas,et al.  Artesunate: could be an alternative drug to chloroquine in COVID-19 treatment? , 2020, Chinese Medicine.

[17]  Matthew J. O’Meara,et al.  Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19 , 2020, bioRxiv.

[18]  Yuichi Kubota,et al.  Potential role of zinc supplementation in prophylaxis and treatment of COVID-19 , 2020, Medical Hypotheses.

[19]  E. M. Anpilogova,et al.  Apremilast as a potential treatment option for COVID‐19: No symptoms of infection in a psoriatic patient , 2020, Dermatologic therapy.

[20]  Y. Prakash,et al.  Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells , 2020, American journal of physiology. Lung cellular and molecular physiology.

[21]  Jun Kobayashi,et al.  Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome , 2020, Annals of Intensive Care.

[22]  O. Glebov.  Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing , 2020, The FEBS journal.

[23]  R. Ureshino,et al.  17β-Estradiol, a potential ally to alleviate SARS-CoV-2 infection , 2020, Clinics.

[24]  Huey-Kang Sytwu,et al.  Artificial intelligence approach fighting COVID-19 with repurposing drugs , 2020, Biomedical Journal.

[25]  M. Marinella.  Indomethacin and resveratrol as potential treatment adjuncts for SARS‐CoV‐2/COVID‐19 , 2020, International journal of clinical practice.

[26]  S. Ciesek,et al.  Proteomics of SARS-CoV-2-infected host cells reveals therapy targets , 2020, Nature.

[27]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[28]  A. Duttaroy,et al.  Is copper beneficial for COVID-19 patients? , 2020, Medical Hypotheses.

[29]  T. Scalea,et al.  Factor VIII and Functional Protein C Activity in Critically Ill Patients With Coronavirus Disease 2019: A Case Series , 2020, A&A practice.

[30]  G. Martínez-Sánchez,et al.  Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19 , 2020, Antioxidants.

[31]  D. Qu,et al.  Potent antiviral effect of protoporphyrin IX and verteporfin on SARS-CoV-2 infection , 2020 .

[32]  F. Pane,et al.  SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection , 2020, Mediterranean journal of hematology and infectious diseases.

[33]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[34]  Trinath Chowdhury,et al.  In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases. , 2020, Infectious disorders drug targets.

[35]  V. Uversky,et al.  Serum albumin-mediated strategy for the effective targeting of SARS-CoV-2 , 2020, Medical Hypotheses.

[36]  Jerrine Joseph,et al.  Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach , 2020, Journal of biomolecular structure & dynamics.

[37]  M. Barbagallo,et al.  Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature , 2020, Frontiers in Medicine.

[38]  V. Tripathi,et al.  Natural compounds as potential inhibitors of novel coronavirus (COVID-19) main protease: An in silico study , 2020 .

[39]  J. Smeitink,et al.  Hypothesis: mPGES-1-Derived Prostaglandin E2, a So Far Missing Link in COVID-19 Pathophysiology? , 2020 .

[40]  A. Panarese,et al.  Letter: Covid‐19, and vitamin D , 2020, Alimentary pharmacology & therapeutics.

[41]  A. G. de la Fuente,et al.  Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicity—Opportunity for Repurposed Chemotherapy of COVID-19 Infection , 2020, bioRxiv.

[42]  M. Sehailia,et al.  Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19 , 2020, Journal of biomolecular structure & dynamics.

[43]  A. B. Jena,et al.  Catechin and Curcumin interact with corona (2019-nCoV/SARS-CoV2) viral S protein and ACE2 of human cell membrane: insights from Computational study and implication for intervention , 2020 .

[44]  D. Selinger,et al.  Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo , 2020, bioRxiv.

[45]  Lu Zhang,et al.  A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis , 2020, Nutrients.

[46]  De-Ming Yang,et al.  A Review of SARS-CoV-2 and the Ongoing Clinical Trials , 2020, International journal of molecular sciences.

[47]  C. Cava,et al.  In Silico Discovery of Candidate Drugs against Covid-19 , 2020, Viruses.

[48]  Krystal L. Matthews,et al.  SARS-CoV-2 in vitro and SARS-CoV in vivo , 2020 .

[49]  S. Howard,et al.  Drug Repositioning Suggests a Role for the Heat Shock Protein 90 Inhibitor Geldanamycin in Treating COVID-19 Infection , 2020 .

[50]  Wu Zhong,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[51]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[52]  Su Hwan Lee,et al.  Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea , 2020, Journal of Korean medical science.

[53]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[54]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[55]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[56]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[57]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[58]  M. Shi,et al.  Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients , 2020, Emerging microbes & infections.

[59]  F. Sanz,et al.  The DisGeNET knowledge platform for disease genomics: 2019 update , 2019, Nucleic Acids Res..

[60]  G. Soraya,et al.  Estrogen and the Disease Severity of SARS-CoV-2 Infection , 2020 .

[61]  Hydroxychloroquine , 2019, Reactions Weekly.

[62]  Jing Wang,et al.  WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs , 2019, Nucleic Acids Res..

[63]  Othman Soufan,et al.  NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis , 2019, Nucleic Acids Res..

[64]  Anushya Muruganujan,et al.  PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools , 2018, Nucleic Acids Res..

[65]  E. Novellino,et al.  Resveratrol as a Novel Anti-Herpes Simplex Virus Nutraceutical Agent: An Overview , 2018, Viruses.

[66]  Chi-Chen Lin,et al.  Effective inhibition of MERS-CoV infection by resveratrol , 2017, BMC Infectious Diseases.

[67]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[68]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[69]  R. Colwell,et al.  Human Coronavirus 229E Remains Infectious on Common Touch Surface Materials , 2015, mBio.

[70]  Jihye Kim,et al.  DSigDB: drug signatures database for gene set analysis , 2015, Bioinform..

[71]  Karin Breuer,et al.  InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation , 2012, Nucleic Acids Res..

[72]  A. Ashkar,et al.  The Nitric Oxide Pathway Provides Innate Antiviral Protection in Conjunction with the Type I Interferon Pathway in Fibroblasts , 2012, PloS one.

[73]  Li-Kwan Chang,et al.  Inhibitory Effects of Resveratrol on the Epstein-Barr Virus Lytic Cycle , 2010, Molecules.

[74]  Jing Chen,et al.  ToppGene Suite for gene list enrichment analysis and candidate gene prioritization , 2009, Nucleic Acids Res..

[75]  Mark A. Simmons.  17 Beta Estradiol , 2007 .

[76]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[77]  V. Wong,et al.  Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients , 2004, Journal of Clinical Virology.